Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment
Published: 23 Mar 2026
Author: Precedence Research
Quotient Science is leading integrated CRDMO (contract research, development, and manufacturing organisation), has announced an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.
This collaboration and commitment to reinforce Quotient Science to support the manufacture of niche and smaller volume commercial products, often overlooked by larger contract research, development, and manufacturing organisations.
The FDA approved Sohonos (Palovarotene) in 2023 highly potent molecule that requires specialised handling and containment to protect both the facility and manufacturing operators.
As the partnership grows, Ipsen has invested in new equipment at Quotient Sciences'Boothwyn, including a Pneumatic Closed Transfer System, which ensures safe material transfer without impacting blend segregation, and a Flexible Dispensing Isolator, which enhances operator safety and eliminates special cleaning requirements. It also brings a world-class facility, an experienced team, and reliable supply capabilities, and can also manage global shipments with seamless delivery and operational excellence.
According to Towards Healthcare, the High-Potency Active Pharmaceutical Ingredients (HPAPI) Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 33.45 billion in 2026 to approximately USD 69.13 billion by 2035, representing a compound annual growth rate (CAGR) of 8.4% from 2026 to 2035. The partnership ensures sustained commercial supply for FOP therapy and broadens capabilities to handle multiple highly potent compounds at commercial scale, addressing critical needs in rare disease treatment.
Unwavering Commitment to Support Patients
General Manager, Quotient Sciences, Philadelphia, Marlene Leuenberger, stated about this significant investment in advanced containment and manufacturing technology at the Boothwyn facility, committing to support patients with ultra-rare diseases. By expanding capabilities to handle multiple highly potent compounds at a commercial scale, noting critical needs in rare disease treatment. It also promises to reinforce its promise to deliver flexible, high-quality solutions for our partners with specialised needs, especially for highly potent compounds.
A recent report by Towards Healthcare highlights that the High-Potency Active Pharmaceutical Ingredients (HPAPI) Market is experiencing trust for integrated drug product formulation development and manufacturing, with clinical testing activities. It also promises to deliver flexible, high-quality solutions for our partners with specialised needs.